secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124636
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology Q3 net loss $20.4M; cash $540.7M, runway through 2027
-----------------------------------------------------------------

- Net loss of $20.4M ($0.30 per share) vs $17.5M ($4.00) in Q3 2023.
- Cash and securities $540.7M as of Sept 30, 2024; expects to fund operations through 2027.
- R&D expenses $19.6M (up from $11.7M) driven by clinical trial and CMC costs.
- G&A expenses $8.7M (up from $2.3M) due to personnel, professional fees, insurance.
- Phase 3 BOND-003 cretostimogene results accepted as late-breaking abstract at SUO 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000095017024124636/0000950170-24-124636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000095017024124636/ck0001991792-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer